Christian Hoyer Millar MA, Hons (Oxon)
Christian was awarded a scholarship to read Politics, Philosophy and Economics at Lincoln College, Oxford. His career started at the Boston Consulting Group where he worked both in Europe and USA. He then moved to the UK Holding Company of the German/Dutch Conglomerate, Hoogovens, as a director of a number of the subsidiaries in the UK, winning the Queen’s award for exports.
Hoyer Millar then became a Vice President of Fox Pitt Kelton, where he worked on the mergers and acquisitions of US Regional Banks until the company went public at which point he was head-hunted to run a venture capital firm in conjunction with Ensign Trust PLC, owned by the Merchant Navy Pension Fund.
Since then Hoyer Millar has worked in venture capital including as a founder of an Ofex listed company and a founding shareholder in an AIM listed company. He is additionally CEO of Oxford Biodynamics Limited, an Oxford University spin-out diagnostic company, and has extensive commercial experience in the USA and Asia.
Dr. Huw Jones PhD
Chief Executive Officer
Huw holds a PhD in pharmacology from the University of Birmingham, UK and has over twenty years experience in the pharmaceutical sector. He has supervised over fifteen product launches in Europe and has completed numerous product and company acquisitions and divestments.
Most recently Huw has been working with Atlantic Pharmaceuticals to lead growth of Atlantic Healthcare’s therapeutics division. Huw was a director of Ardana plc and was previously President, Europe for CV Therapeutics Inc, a NASDAQ-quoted pharmaceutical company recently acquired by Gilead Sciences Inc. for US$1.4bn. Other appointments include Senior Vice President, Northern Europe, for Elan Pharmaceuticals where he helped build the European operations from a start-up into a 600 person division and UK marketing director for SmithKlineBeecham Pharmaceuticals, now part of GlaxoSmithKline plc.
Dr. Michael Moore Phd, DSc, FRCpath
Michael Moore began his career at the Paterson Institute for Cancer Research and Manchester University, where he was Reader in Experimental Oncology and Immunology and sometime Editor-in Chief of the British Journal of Cancer.
He entered the UK Biotechnology industry in 1989, subsequently becoming a director of Xenova Group which went public on NASDAQ (1994) and LSE (1996). He facilitated the divestment of the Group’s drug discovery division, assisted in the consolidation of Xenova as an oncology-focussed business and played a major role in the acquisition and integration of the biologics company Cantab Pharmaceuticals (2000) in the capacity of Chief Scientific Officer.
In 2002, Dr Moore became Chief Executive Officer of Piramed Limited, a private UK-based biotechnology company dedicated to the discovery and development of small molecule inhibitors of PI 3-kinases. Piramed is credited with bringing this new class of drug to clinical trial on behalf of Cancer Research UK, Institute of Cancer Research and Ludwig Institute for Cancer Research. Piramed entered into collaboration with Genentech in 2005 with a headline valuation of $230 million and was subsequently acquired by Roche in 2008.
Dr Moore practises as a biopharmaceutical consultant and business angel with a portfolio of non-executive directorships, including Chairman of Trillium Therapeutics Inc, a private Toronto-based biologics company, Myotec, a speciality pharma company spun out of Imperial College London and Charité University, Berlin and Oxford BioTherapeutics, a cancer antibody therapy-based company. He is also a Professor Associate in the Department of Cancer Genetics and Pharmacogenomics in the Brunel Institute.
Martin Diggle MA (Oxon)
Martin is a founder of Vulpes Investment Management, a Cayman Fund Manager which currently manages five funds including the Vulpes Life Sciences Fund; Chronos Therapeutics’ largest shareholder. An investment professional with over 29 years’ experience in investment banking and fund management, Martin has extensive, first-hand knowledge of the global financial markets.
Martin has been an investor in life sciences and biotechnology since 1999 and has developed a passionate interest in the sector having worked closely with several companies as a stakeholder over the past decade.
Alexandre Akoulitchev MA, Hons (Oxon), PhD, FRSM
Sasha read mathematics, physics, chemistry, biochemistry and biophysics at the Moscow Institute of Physics and Technology. In 1989, he was selected by the George Soros Foundation to study for a year at the University of Oxford along with other 20 top Soviet graduate students. In 1994 he obtained his PhD in cell biology from University College London (with his research based at the Imperial Cancer Research Fund). Sasha spent six years at the Robert Wood Johnson Medical School, NJ, USA as a research assistant funded by the Howard Hughes Medical Institute.
Upon his return to England in 2001, he was awarded with The Wellcome Trust Carrier Development Fellowship and has established a research laboratory at the Sir William Dunn School of Pathology, University of Oxford, with the focus on biochemistry of transcriptional mechanisms, non-coding regulatory RNAs and early epigenetic events. The research of the lab was supported by Cancer Research UK, Wellcome Trust and the Medical Research Council. Its results were widely publicized.
Before moving full-time to Oxford BioDynamics as a Company Director in 2007, Sasha was a University Academic Fellow (Research Council UK) and a Senior Fellow of Exeter College.
Professor Jane Mellor PhD University of Oxford
Jane read bacteriology and virology at the University of Manchester and got her PhD from the University of Reading (with his research based at the Institute for Animal Health). She started her career as a post doctoral research scientist at the University of Oxford. She then moved on to become a research fellow at Wolfson and Exeter colleges, Oxford University. In 1989, she became a Wellcome Trust Senior Research Fellow in basic biomedical sciences. Her teaching career started in 1991 and to date she has tutored and supervised more than 20 graduate students gaining their DPhil degrees. Jane has published more than 70 articles in peer reviewed journals and in 2008 was made the first Professor of Epigenetics at the University of Oxford.